WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...

Luckily, 2025 has given werewolf enthusiasts one of the best stories focusing on the supernatural beasts in recent memory, and it’s a shame that many might have missed it. Earlier this year, writer ...

Citizens downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform without a price target after the company provided updates to ...

On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER platforms, highlighting preliminary clinical data and a shift ...

As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Following the official Marvel Cinematic Universe debut of fan-favorite villain Mephisto, it seems like Marvel Studios is ready to embrace more of the MCU’s supernatural side. That’s why, after more ...